Chosa Oncology AB ("Chosa" or the "Company") today announces the result of the exercise of warrants series TO 2, which were issued in connection with the Company's issue of units in the second quarter of 2025. The result shows that a total of 3,577,285 warrants series TO 2 were exercised for subscription of 3,577,285 new shares in the Company, corresponding to approximately 45 percent of the total number of issued warrants series TO 2. Through the exercise, Chosa receives approximately SEK 2.8 million before transaction costs.
In the second quarter of 2025, Chosa conducted an issue of units consisting of shares and warrants, where every unit consisted of one (1) share and one (1) warrant series TO 2. In total, 7,951,740 warrants series TO 2 were issued. Every one (1) warrant entitled the holder to subscribe for one (1) new share in Chosa. The subscription price per share was set to SEK 0.78.
The subscription period is now complete and the result shows that a total of 3,577,285 warrants series TO 2 were exercised for subscription of 3,577,285 new shares in the Company, corresponding to approximately 45 percent of the total number of issued warrants series TO 2. This will bring a total of approximately SEK 2.8 million to Chosa before transaction costs.
Through the exercise of 3,577,285 warrants series TO 2, the number of shares in Chosa increases with 3,577,285 shares to 91,440,957 shares, and the share capital increases with SEK 643,911.30 to SEK 16,459,372.26. This entails a dilution of approximately 3.9 percent based on the number of outstanding shares in Chosa.
Financial advisor, issuing agent and legal advisor
Västra Hamnen Corporate Finance AB is financial advisor and Nordic Issuing AB act as issuing agent to Chosa in connection with the exercise of warrants series TO 2. Setterwalls Advokatbyrå AB is legal advisor.
For further information, please contact:
Peter Buhl Jensen, CEO
peter@chosa.bio
+45 21 60 89 22
About Chosa Oncology AB (publ)
CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression-based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit from treatment, CHOSA aims to improve treatment outcomes and optimise treatment choices in cancer care.
Important information
This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 (the Prospectus Regulation) and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been prepared in connection with the rights issue of units consisting of shares and warrants of series TO 2. The Company has prepared an information document in the form provided for in Annex IX of the Prospectus Regulation (the "Information Document"). The Information Document is available on the Company's website, www.chosaoncology.com. The Swedish Financial Supervisory Authority, which is the national competent authority, has not approved nor reviewed the Information Document. Each investor is advised to make their own assessment of whether it is appropriate to invest in the Company.
This press release does not constitute an offer to, or solicitation of, acquire or subscribe for any securities in the Company in any jurisdiction, either from the Company or any other party. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where such release, publication or distribution of this information would be contrary to applicable rules or where such action is subject to legal restrictions. Actions in breach of these instructions may constitute a violation of applicable securities legislation.
.